Tokyo Tape
Sign in
← Falco Holdings

Quarterly report · Q2

4671.TEDINET S100PKQ2
Period2022-04-01 → 2022-09-30
Filed2022-11-11
StandardJapan GAAP
ConsolidatedYes
Data checks14 of 14 passed
Key figures · 49
MetricValuePeriodScopeSource row
Revenue¥24.2bn2022-04-01 → 2022-09-30Cons.Net sales
Revenue¥50.0bn2021-04-01 → 2022-03-31Cons.Net sales (5-year summary)
Revenue¥24.7bn2021-04-01 → 2021-09-30Cons.Net sales
Operating income¥1.7bn2022-04-01 → 2022-09-30Cons.Operating income
Operating income¥3.1bn2021-04-01 → 2021-09-30Cons.Operating income
Ordinary income¥1.9bn2022-04-01 → 2022-09-30Cons.Ordinary income
Ordinary income¥5.8bn2021-04-01 → 2022-03-31Cons.Ordinary income loss (5-year summary)
Ordinary income¥3.3bn2021-04-01 → 2021-09-30Cons.Ordinary income
Profit before tax¥1.9bn2022-04-01 → 2022-09-30Cons.Income before income taxes
Profit before tax¥3.3bn2021-04-01 → 2021-09-30Cons.Income before income taxes
Net income (owners)¥1.1bn2022-04-01 → 2022-09-30Cons.Profit loss attributable to owners of parent
Net income (owners)¥3.5bn2021-04-01 → 2022-03-31Cons.Profit loss attributable to owners of parent (5-year summary)
Net income (owners)¥2.1bn2021-04-01 → 2021-09-30Cons.Profit loss attributable to owners of parent
Net income¥1.1bn2022-04-01 → 2022-09-30Cons.Profit loss
Net income¥2.1bn2021-04-01 → 2021-09-30Cons.Profit loss
Total assets¥38.7bnat 2022-09-30Cons.Assets
Total assets¥40.3bnat 2022-03-31Cons.Assets
Total assets¥39.1bnat 2021-09-30Cons.Total assets (5-year summary)
Total liabilities¥14.4bnat 2022-09-30Cons.Liabilities
Total liabilities¥16.8bnat 2022-03-31Cons.Liabilities
Net assets / equity¥24.3bnat 2022-09-30Cons.Net assets
Net assets / equity¥23.5bnat 2022-03-31Cons.Net assets
Net assets / equity¥22.4bnat 2021-09-30Cons.Net assets (5-year summary)
Cash and deposits¥10.9bnat 2022-09-30Cons.Cash and deposits
Cash and deposits¥10.6bnat 2022-03-31Cons.Cash and deposits
Cash & equivalents¥10.9bnat 2022-09-30Cons.Cash and cash equivalents
Cash & equivalents¥10.6bnat 2022-03-31Cons.Cash and cash equivalents
Cash & equivalents¥12.1bnat 2021-09-30Cons.Cash and cash equivalents
Cash & equivalents¥11.6bnat 2021-03-31dCons.Cash and cash equivalents
Operating cash flow¥1.5bn2022-04-01 → 2022-09-30Cons.Net cash provided by used in operating activities
Operating cash flow¥4.1bn2021-04-01 → 2022-03-31Cons.Net cash provided by used in operating activities (5-year summary)
Operating cash flow¥2.0bn2021-04-01 → 2021-09-30Cons.Net cash provided by used in operating activities
Investing cash flow−¥249m2022-04-01 → 2022-09-30Cons.Net cash provided by used in investment activities
Investing cash flow−¥2.7bn2021-04-01 → 2022-03-31Cons.Net cash provided by used in investing activities (5-year summary)
Investing cash flow−¥503m2021-04-01 → 2021-09-30Cons.Net cash provided by used in investment activities
Financing cash flow−¥937m2022-04-01 → 2022-09-30Cons.Net cash provided by used in financing activities
Financing cash flow−¥2.4bn2021-04-01 → 2022-03-31Cons.Net cash provided by used in financing activities (5-year summary)
Financing cash flow−¥1.0bn2021-04-01 → 2021-09-30Cons.Net cash provided by used in financing activities
EPS (basic)¥107.52022-04-01 → 2022-09-30Cons.Basic earnings loss per share (5-year summary)
EPS (basic)¥65.162022-07-01 → 2022-09-30dCons.Basic earnings loss per share (5-year summary)
EPS (basic)¥3392021-04-01 → 2022-03-31Cons.Basic earnings loss per share (5-year summary)
EPS (basic)¥204.382021-04-01 → 2021-09-30Cons.Basic earnings loss per share (5-year summary)
EPS (basic)¥122.92021-07-01 → 2021-09-30dCons.Basic earnings loss per share (5-year summary)
EPS (diluted)¥107.182022-04-01 → 2022-09-30Cons.Diluted earnings per share (5-year summary)
EPS (diluted)¥336.992021-04-01 → 2022-03-31Cons.Diluted earnings per share (5-year summary)
EPS (diluted)¥203.772021-04-01 → 2021-09-30Cons.Diluted earnings per share (5-year summary)
Equity ratio62.6%at 2022-09-30Cons.Equity to asset ratio (5-year summary)
Equity ratio58.1%at 2022-03-31Cons.Equity to asset ratio (5-year summary)
Equity ratio57.1%at 2021-09-30Cons.Equity to asset ratio (5-year summary)

Periods use the dates stated in the filing. d = earlier-year period dated by calendar; v = that date confirmed by the company's own earlier filing.

Segments · 30
SegmentItemPeriodValue
Reconciling Itemsreconcilingrevenue2022-04-01 → 2022-09-30−¥4m
Reconciling Itemsreconcilingrevenue intersegment2022-04-01 → 2022-09-30−¥4m
Reconciling Itemsreconcilingsegment profit2022-04-01 → 2022-09-30−¥213m
jpcrp040300-q2r_E04982-000Clinical Testing Businessreportable segmentrevenue2022-04-01 → 2022-09-30¥16.2bn
jpcrp040300-q2r_E04982-000Clinical Testing Businessreportable segmentrevenue external2022-04-01 → 2022-09-30¥16.2bn
jpcrp040300-q2r_E04982-000Clinical Testing Businessreportable segmentrevenue intersegment2022-04-01 → 2022-09-30¥4m
jpcrp040300-q2r_E04982-000Clinical Testing Businessreportable segmentsegment profit2022-04-01 → 2022-09-30¥1.6bn
jpcrp040300-q2r_E04982-000Dispensing Pharmacy Businessreportable segmentrevenue2022-04-01 → 2022-09-30¥7.9bn
jpcrp040300-q2r_E04982-000Dispensing Pharmacy Businessreportable segmentrevenue external2022-04-01 → 2022-09-30¥7.9bn
jpcrp040300-q2r_E04982-000Dispensing Pharmacy Businessreportable segmentrevenue intersegment2022-04-01 → 2022-09-30¥0
jpcrp040300-q2r_E04982-000Dispensing Pharmacy Businessreportable segmentsegment profit2022-04-01 → 2022-09-30¥320m
—segment totalrevenue2022-04-01 → 2022-09-30¥24.2bn
—segment totalrevenue external2022-04-01 → 2022-09-30¥24.2bn
—segment totalrevenue intersegment2022-04-01 → 2022-09-30¥4m
—segment totalsegment profit2022-04-01 → 2022-09-30¥2.0bn
Reconciling Itemsreconcilingrevenue2021-04-01 → 2021-09-30−¥8m
Reconciling Itemsreconcilingrevenue intersegment2021-04-01 → 2021-09-30−¥8m
Reconciling Itemsreconcilingsegment profit2021-04-01 → 2021-09-30−¥177m
jpcrp040300-q2r_E04982-000Clinical Testing Businessreportable segmentrevenue2021-04-01 → 2021-09-30¥16.6bn
jpcrp040300-q2r_E04982-000Clinical Testing Businessreportable segmentrevenue external2021-04-01 → 2021-09-30¥16.6bn
jpcrp040300-q2r_E04982-000Clinical Testing Businessreportable segmentrevenue intersegment2021-04-01 → 2021-09-30¥7m
jpcrp040300-q2r_E04982-000Clinical Testing Businessreportable segmentsegment profit2021-04-01 → 2021-09-30¥2.8bn
jpcrp040300-q2r_E04982-000Dispensing Pharmacy Businessreportable segmentrevenue2021-04-01 → 2021-09-30¥8.1bn
jpcrp040300-q2r_E04982-000Dispensing Pharmacy Businessreportable segmentrevenue external2021-04-01 → 2021-09-30¥8.1bn
jpcrp040300-q2r_E04982-000Dispensing Pharmacy Businessreportable segmentrevenue intersegment2021-04-01 → 2021-09-30¥0
jpcrp040300-q2r_E04982-000Dispensing Pharmacy Businessreportable segmentsegment profit2021-04-01 → 2021-09-30¥523m
—segment totalrevenue2021-04-01 → 2021-09-30¥24.7bn
—segment totalrevenue external2021-04-01 → 2021-09-30¥24.7bn
—segment totalrevenue intersegment2021-04-01 → 2021-09-30¥8m
—segment totalsegment profit2021-04-01 → 2021-09-30¥3.3bn

Segment names come from EDINET member IDs; not yet mapped to a common taxonomy.

All source rows · 519
ItemContextValueUnit
Salaries and bonuses sgaPrior1YTDDuration1913000000JPY
Salaries and bonuses sgaCurrentYTDDuration1915000000JPY
Provision for bonuses sgaPrior1YTDDuration231000000JPY
Provision for bonuses sgaCurrentYTDDuration238000000JPY
Retirement benefit expenses sgaPrior1YTDDuration57000000JPY
Retirement benefit expenses sgaCurrentYTDDuration62000000JPY
Provision for directors retirement benefits sgaPrior1YTDDuration23000000JPY
Provision for directors retirement benefits sgaCurrentYTDDuration－JPY
Welfare expenses sgaPrior1YTDDuration505000000JPY
Welfare expenses sgaCurrentYTDDuration618000000JPY
Depreciation sgaPrior1YTDDuration106000000JPY
Depreciation sgaCurrentYTDDuration111000000JPY
Rent expenses sgaPrior1YTDDuration292000000JPY
Rent expenses sgaCurrentYTDDuration287000000JPY
Supplies expenses sgaPrior1YTDDuration550000000JPY
Supplies expenses sgaCurrentYTDDuration614000000JPY
Amortization of goodwill sgaPrior1YTDDuration8000000JPY
Amortization of goodwill sgaCurrentYTDDuration8000000JPY
Miscellaneous expenses sgaPrior1YTDDuration162000000JPY
Miscellaneous expenses sgaCurrentYTDDuration194000000JPY
Revenues from external customersPrior1YTDDuration_jpcrp040300-q2r_E04982-000ClinicalTestingBusinessReportableSegmentsMember16640000000JPY
Revenues from external customersPrior1YTDDuration_jpcrp040300-q2r_E04982-000DispensingPharmacyBusinessReportableSegmentsMember8053000000JPY
Revenues from external customersPrior1YTDDuration_ReportableSegmentsMember24693000000JPY
Revenues from external customersPrior1YTDDuration_ReconcilingItemsMember－JPY
Revenues from external customersPrior1YTDDuration24693000000JPY
Transactions with other segmentsPrior1YTDDuration_jpcrp040300-q2r_E04982-000ClinicalTestingBusinessReportableSegmentsMember7000000JPY
Transactions with other segmentsPrior1YTDDuration_jpcrp040300-q2r_E04982-000DispensingPharmacyBusinessReportableSegmentsMember0JPY
Transactions with other segmentsPrior1YTDDuration_ReportableSegmentsMember8000000JPY
Transactions with other segmentsPrior1YTDDuration_ReconcilingItemsMember-8000000JPY
Transactions with other segmentsPrior1YTDDuration－JPY
Net salesPrior1YTDDuration_jpcrp040300-q2r_E04982-000ClinicalTestingBusinessReportableSegmentsMember16648000000JPY
Net salesPrior1YTDDuration_jpcrp040300-q2r_E04982-000DispensingPharmacyBusinessReportableSegmentsMember8053000000JPY
Net salesPrior1YTDDuration_ReportableSegmentsMember24701000000JPY
Net salesPrior1YTDDuration_ReconcilingItemsMember-8000000JPY
Net salesPrior1YTDDuration24693000000JPY
Operating incomePrior1YTDDuration_jpcrp040300-q2r_E04982-000ClinicalTestingBusinessReportableSegmentsMember2790000000JPY
Operating incomePrior1YTDDuration_jpcrp040300-q2r_E04982-000DispensingPharmacyBusinessReportableSegmentsMember523000000JPY
Operating incomePrior1YTDDuration_ReportableSegmentsMember3313000000JPY
Operating incomePrior1YTDDuration_ReconcilingItemsMember-177000000JPY
Operating incomePrior1YTDDuration3136000000JPY
Revenues from external customersCurrentYTDDuration_jpcrp040300-q2r_E04982-000ClinicalTestingBusinessReportableSegmentsMember16238000000JPY
Revenues from external customersCurrentYTDDuration_jpcrp040300-q2r_E04982-000DispensingPharmacyBusinessReportableSegmentsMember7913000000JPY
Revenues from external customersCurrentYTDDuration_ReportableSegmentsMember24151000000JPY
Revenues from external customersCurrentYTDDuration_ReconcilingItemsMember－JPY
Revenues from external customersCurrentYTDDuration24151000000JPY
Transactions with other segmentsCurrentYTDDuration_jpcrp040300-q2r_E04982-000ClinicalTestingBusinessReportableSegmentsMember4000000JPY
Transactions with other segmentsCurrentYTDDuration_jpcrp040300-q2r_E04982-000DispensingPharmacyBusinessReportableSegmentsMember0JPY
Transactions with other segmentsCurrentYTDDuration_ReportableSegmentsMember4000000JPY
Transactions with other segmentsCurrentYTDDuration_ReconcilingItemsMember-4000000JPY
Transactions with other segmentsCurrentYTDDuration－JPY

Every row of the EDINET CSV. Item names are the XBRL element names; filed text is kept in its original Japanese. Filed text is available on Plus and Pro.

Data checks · 14 of 14 passed
balance sheet identityconsolidated 2022-03-31pass
balance sheet identityconsolidated 2022-09-30pass
dei present pass
period resolution pass
statement vs summary · net assetsconsolidated 2022-03-31pass
statement vs summary · net assetsconsolidated 2022-09-30pass
statement vs summary · net income attributable to parentconsolidated 2021-04-01/2021-09-30pass
statement vs summary · net income attributable to parentconsolidated 2022-04-01/2022-09-30pass
statement vs summary · operating cash flowconsolidated 2021-04-01/2021-09-30pass
statement vs summary · operating cash flowconsolidated 2022-04-01/2022-09-30pass
statement vs summary · revenueconsolidated 2021-04-01/2021-09-30pass
statement vs summary · revenueconsolidated 2022-04-01/2022-09-30pass
statement vs summary · total assetsconsolidated 2022-03-31pass
statement vs summary · total assetsconsolidated 2022-09-30pass